Photo: businesstech.co.za
Aspen's New Weight Loss Drug Gains Approval to Compete with Ozempic in SA
Aspens new weight loss medication, Mounjaro (tirzepatide), has gained regulatory approval in South Africa, positioning it as a competitor to Ozempic in obesity treatment.
- Aspen received approval from the South African Health Products Regulatory Authority for Mounjaro (tirzepatide), a weekly prescription medication for chronic weight management effective October 2025.
- Mounjaro is intended as an adjunct to a reduced-calorie diet and increased physical activity, targeting individuals struggling with obesity and related conditions like Type 2 diabetes.
- Aspen aims to compete against established medications like Ozempic and semaglutide, addressing the growing demand for effective weight loss solutions in South Africa.
Why It Matters
The approval of Mounjaro (tirzepatide) signifies a pivotal moment in the fight against obesity in South Africa, offering new options for weight management and Type 2 diabetes, amidst rising health concerns.